Paris-based Spore.Bio, a deeptech startup applying machine learning to microbiology testing, has secured $23 million in Series A funding.
The round was led by Singular, with participation from Point 72 Ventures, 1st Kind Ventures, Station F, Lord David Prior, LocalGlobe, No Label Ventures, and Famille C.
Faster, AI-Powered Contamination Detection
Spore.Bio is transforming food safety, cosmetics, and pharmaceuticals by replacing traditional microbiology testing methods, which can take days or even weeks. Instead of relying on petri-dish cultures, Spore.Bio:
- Uses AI and spectral analysis to detect bacteria in minutes
- Eliminates the need for offsite lab testing, allowing on-site contamination monitoring
- Partners with the Pasteur Institute for access to a vast database of bacterial samples
CEO Amine Raji, a former Nestlé manufacturing engineer, explained:
“Food and pharmaceutical companies operate in real time—waiting days for test results creates unacceptable delays. Our technology makes microbiology testing as fast as the rest of the production process.”
Advertisement
Expanding Beyond Food Safety
Originally focused on preventing food contamination, Spore.Bio has also gained interest from:
- Cosmetic companies, which are reducing preservatives but need enhanced bacterial safety
- Pharmaceutical firms, particularly those working with cell and gene therapies that have ultra-short shelf lives
Scaling with New Funding
With its latest funding the startup plans to:
- Expand its AI-powered microbiology testing machines for factory use
- Increase its team from 30 to 50 employees by the end of 2025
- Scale commercial contracts, after already securing 200 factory partnerships
By enabling instant bacterial detection, Spore.Bio is setting a new standard for real-time microbiology testing, making industries safer, more efficient, and less reliant on outdated methods.
